Ovarian cancer cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Ovarian cancer}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. == References == {{re..." |
|||
| (7 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Ovarian cancer}} | |||
{{ | {{CMG}}; {{AE}}, {{Hudakarman}} | ||
==Overview== | |||
The [[management]] of [[ovarian cancer]] is composed of [[surgery]] and [[chemotherapy]] that can be either [[adjuvant]] or [[neoadjuvant]] depending on the stage and grade of the [[tumor]] and on the condition and function of the patient. [[Bevacizumab]] in addition to [[chemotherapy]] is a [[cost-effective]] alternative for [[ovarian cancer]] patients who are at high risk of progression. | |||
==Cost-effectiveness of therapy== | |||
* The [[management]] of [[ovarian cancer]] is composed of [[surgery]] and [[chemotherapy]] that can be either [[adjuvant]] or [[neoadjuvant]] depending on the stage and grade of the [[tumor]] and on the condition and function of the patient.<ref name="Martín-CameáDelgado-Sánchez2016">{{cite journal|last1=Martín-Cameá|first1=María|last2=Delgado-Sánchez|first2=Elsa|last3=Piñera|first3=Antonio|last4=Diestro|first4=Maria Dolores|last5=De Santiago|first5=Javier|last6=Zapardiel|first6=Ignacio|title=The role of surgery in advanced epithelial ovarian cancer|journal=ecancermedicalscience|volume=10|year=2016|issn=17546605|doi=10.3332/ecancer.2016.666}}</ref> | |||
*[[Bevacizumab]] in addition to [[chemotherapy]] is a [[cost-effective]] alternative for [[ovarian cancer]] patients who are at high risk of progression.<ref name="DuongWright2016">{{cite journal|last1=Duong|first1=M.|last2=Wright|first2=E.|last3=Martin-Nunez|first3=I.|last4=Yin|first4=L.|last5=Ghatage|first5=P.|last6=Fung-Kee-Fung|first6=M.|title=The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada|journal=Current Oncology|volume=23|issue=5|year=2016|pages=461|issn=1718-7729|doi=10.3747/co.23.3139}}</ref> | |||
== References == | == References == | ||
| Line 13: | Line 19: | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Gynecology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 15:59, 13 September 2019
|
Ovarian cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ovarian cancer cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Ovarian cancer cost-effectiveness of therapy |
|
Risk calculators and risk factors for Ovarian cancer cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: , Huda A. Karman, M.D.
Overview
The management of ovarian cancer is composed of surgery and chemotherapy that can be either adjuvant or neoadjuvant depending on the stage and grade of the tumor and on the condition and function of the patient. Bevacizumab in addition to chemotherapy is a cost-effective alternative for ovarian cancer patients who are at high risk of progression.
Cost-effectiveness of therapy
- The management of ovarian cancer is composed of surgery and chemotherapy that can be either adjuvant or neoadjuvant depending on the stage and grade of the tumor and on the condition and function of the patient.[1]
- Bevacizumab in addition to chemotherapy is a cost-effective alternative for ovarian cancer patients who are at high risk of progression.[2]
References
- ↑ Martín-Cameá, María; Delgado-Sánchez, Elsa; Piñera, Antonio; Diestro, Maria Dolores; De Santiago, Javier; Zapardiel, Ignacio (2016). "The role of surgery in advanced epithelial ovarian cancer". ecancermedicalscience. 10. doi:10.3332/ecancer.2016.666. ISSN 1754-6605.
- ↑ Duong, M.; Wright, E.; Martin-Nunez, I.; Yin, L.; Ghatage, P.; Fung-Kee-Fung, M. (2016). "The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada". Current Oncology. 23 (5): 461. doi:10.3747/co.23.3139. ISSN 1718-7729.